{"id":15321,"date":"2022-01-11T23:05:38","date_gmt":"2022-01-11T17:35:38","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=15321"},"modified":"2022-01-11T23:27:07","modified_gmt":"2022-01-11T17:57:07","slug":"pharma-news-for-noxxon-nuvalent-stryker-exact-sciences","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-noxxon-nuvalent-stryker-exact-sciences","title":{"rendered":"Noxxon\u2019s NOX-A12 clinical trial; Exact Sciences buys PreventionGenetics; Nuvalent\u2019s clinical trails for NVL-520; Stryker acquires Vocera Communications"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fcd6b870f3b\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fcd6b870f3b\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-noxxon-nuvalent-stryker-exact-sciences\/#Noxxon_continues_enrolment_in_a_glioblastoma_therapy_trial\" >Noxxon continues enrolment in a glioblastoma therapy trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-noxxon-nuvalent-stryker-exact-sciences\/#Exact_Sciences_buys_PreventionGenetics_in_USD_190_Million_deal\" >Exact Sciences buys PreventionGenetics in USD 190 Million deal<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-noxxon-nuvalent-stryker-exact-sciences\/#Nuvalent_doses_first_subject_in_Phase_III_trial_of_NSCLC_therapy\" >Nuvalent doses first subject in Phase I\/II trial of NSCLC therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-noxxon-nuvalent-stryker-exact-sciences\/#Stryker_acquires_Vocera_Communications_for_USD_29_Billion\" >Stryker acquires Vocera Communications for USD 2.9 Billion&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-noxxon-continues-enrolment-in-a-glioblastoma-therapy-trial\"><span class=\"ez-toc-section\" id=\"Noxxon_continues_enrolment_in_a_glioblastoma_therapy_trial\"><\/span><strong>Noxxon continues enrolment in a glioblastoma therapy trial<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Noxxon Pharma continues subject enrolment in the GLORIA clinical trial of NOX-A12 in <a href=\"https:\/\/www.delveinsight.com\/report-store\/glioblastoma-epidemiology-forecast\">brain cancer (glioblastoma) patients<\/a>. The move comes after the Data Safety Monitoring Board (DSMB) evaluated safety results from the preliminary four-week treatment with NOX-A12 plus radiotherapy and <a href=\"https:\/\/www.delveinsight.com\/report-store\/bevacizumab-biosimilars-insight\">bevacizumab <\/a>in the first subject in the expansion arm of the trial.<\/p>\n\n\n\n<p>The DSMB concluded that the treatment is safe and suitable to go further with recruitment to enroll five more subjects into this arm as per the trial protocol. Moreover, the company noticed that the German Federal Institute for Drugs and Medical Devices (Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte) approved the third expansion arm of the trial.<\/p>\n\n\n\n<p>Subjects in this arm will be given NOX-A12 plus pembrolizumab, an inhibitor of programmed cell death protein 1 (PD-1) immune checkpoint, and radiotherapy.<\/p>\n\n\n\n<p>In the GLORIA Phase I\/II trial, the safety and efficacy of NOX-A12 plus radiotherapy will be evaluated in recently detected <a href=\"https:\/\/www.delveinsight.com\/report-store\/glioblastoma-market\"><strong>glioblastoma<\/strong><\/a> in subjects with unmethylated MGMT promoters. Three expansion arms of the trial will each enroll six subjects to evaluate NOX-A12 advantage in several treatment settings.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Exact_Sciences_buys_PreventionGenetics_in_USD_190_Million_deal\"><\/span><strong>Exact Sciences buys PreventionGenetics in USD 190 Million deal<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Exact Sciences, a cancer screening and diagnostic tests provider has bought PreventionGenetics in an agreement worth around USD 190 Million. The deal comprises 50% in Exact Sciences common stock and 50% in cash.<\/p>\n\n\n\n<p>PreventionGenetics is a genetic testing laboratory proffering the clinical lab, expertise, and foundational technology to boost access to hereditary cancer testing (HCT) to benefit patients to assess their germline <a href=\"https:\/\/www.delveinsight.com\/blog\/most-common-cancers-2\">risk of cancer<\/a> and other diseases. The CLIA-certified and CAP-accredited clinical DNA testing laboratory delivers over 5,000 predefined genetic tests for approximately all clinically relevant genes and additional custom panels.<\/p>\n\n\n\n<p>PreventionGenetics delivers a thorough germline whole genome sequencing test called PGnome and a whole-exome sequencing test known as PGxome. Exact Sciences\u2019 Cologuard and Oncotype DX tests are used by more than 300,000 health care providers in primary care, <a href=\"https:\/\/www.delveinsight.com\/blog\/femtech-market\">women\u2019s health<\/a>, oncology, and other specialties.<\/p>\n\n\n\n<p>In collaboration with the PreventionGenetics team, Exact Sciences focuses on leveraging its commercial presence in diagnostics and expanding hereditary cancer and genetic testing across the US and globally. XMS Capital acted as financial advisor to Exact Sciences on the transaction, while K&amp;L Gates served as its legal advisor. CrossTree Capital acted as financial advisor to PreventionGenetics, while Winston &amp; Strawn served as legal advisor.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Nuvalent_doses_first_subject_in_Phase_III_trial_of_NSCLC_therapy\"><\/span><strong>Nuvalent doses first subject in Phase I\/II trial of NSCLC therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Nuvalent has dosed the first subject in the Phase I\/II ARROS-1 clinical trial of NVL-520 in individuals with advanced <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market\">ROS1-positive non-small cell lung cancer (NSCLC)<\/a> and other advanced solid tumors.\u00a0NVL-520 is a brain-penetrant selective inhibitor of ROS1.\u00a0<\/p>\n\n\n\n<p>It can potentially address the clinical challenges of emergent therapy resistance, CNS adverse events, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/brain-metastases-pipeline-insight\">brain metastases<\/a>, limiting the usage of ROS1 <a href=\"https:\/\/www.delveinsight.com\/report-store\/global-kinase-inhibitor-in-autoimmune-diseases-market\">kinase inhibitors<\/a> currently available. The open-label, multicentre, dose-escalation, and expansion trial will evaluate NVL-520 as a single oral agent.\u00a0<\/p>\n\n\n\n<p>The study\u2019s Phase I dose-escalation segment is presently enrolling advanced ROS1-positive solid tumor patients who have earlier got a minimum of one prior ROS1 <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-receptor-tyrosine-kinase-inhibitor-pipeline-insight\">tyrosine kinase inhibitor (TKI) treatment<\/a>.<\/p>\n\n\n\n<p>Moreover, this portion of the trial will analyze the overall tolerability and safety of NVL-520 and determine the recommended Phase II dose (RP2D), assess initial anti-tumor activity, and characterize the pharmacokinetics profile. On choosing a safe and tolerable RP2D, the trial will convert directly to the Phase II multiple cohort expansion segment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Stryker_acquires_Vocera_Communications_for_USD_29_Billion\"><\/span><strong>Stryker acquires Vocera Communications for USD 2.9 Billion&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Medical technology company Stryker has agreed to take over US-based digital care platform Vocera Communications for around USD 2.97 Billion.\u00a0Under the deal, Stryker will acquire all outstanding shares of the common stock of Vocera by paying USD 79.25 per share in cash.<\/p>\n\n\n\n<p>Vocera, established in 2000, proffers communication and workflow solutions to protect and connect team members and enhance the healthcare experience. Vocera solutions are currently utilized by over 2,300 facilities, including 1,900 hospitals and healthcare facilities, to help their workforce communicate and collaborate with co-workers and engage with patients and families.<\/p>\n\n\n\n<p>The solutions integrate over 150 clinical and operational systems, comprising <a href=\"https:\/\/www.delveinsight.com\/blog\/top-healthcare-trends-for-2022\">electronic health records<\/a>, nurse call systems, ventilators, and physiological monitors. The acquisition of Vocera will let Stryker add a complementary and innovative portfolio to its medical division to support hospitals connect caregivers and disparate data-generating medical devices.<\/p>\n\n\n\n<p>Vocera\u2019s software and hardware solutions, which will facilitate secure remote communication between patients and their families, complement Stryker\u2019s advanced digital healthcare offerings.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Noxxon continues enrolment in a glioblastoma therapy trial Noxxon Pharma continues subject enrolment in the GLORIA clinical trial of NOX-A12 in brain cancer (glioblastoma) patients. The move comes after the Data Safety Monitoring Board (DSMB) evaluated safety results from the preliminary four-week treatment with NOX-A12 plus radiotherapy and bevacizumab in the first subject in the [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":15323,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1954,137,841,1787,349,420,1111,639,19003],"industry":[],"therapeutic_areas":[17245,17228,17411],"class_list":["post-15321","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-brain-cancer","tag-cancer","tag-cancer-research","tag-glioblastoma","tag-latest-pharma-news","tag-news","tag-nsclc","tag-pharma-news","tag-womens-health","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-womens-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Noxxon\u2019s NOX-A12 | Stryker acquires Vocera | Nuvalent\u2019s NVL-520<\/title>\n<meta name=\"description\" content=\"Noxxon\u2019s NOX-A12 clinical trial; Exact Sciences buys PreventionGenetics; Nuvalent\u2019s clinical trails for NVL-520; Stryker acquires Vocera\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-noxxon-nuvalent-stryker-exact-sciences\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Noxxon\u2019s NOX-A12 | Stryker acquires Vocera | Nuvalent\u2019s NVL-520\" \/>\n<meta property=\"og:description\" content=\"Noxxon\u2019s NOX-A12 clinical trial; Exact Sciences buys PreventionGenetics; Nuvalent\u2019s clinical trails for NVL-520; Stryker acquires Vocera\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-noxxon-nuvalent-stryker-exact-sciences\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-11T17:35:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-11T17:57:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/11230453\/Pharma-News-11.01.2022-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Noxxon\u2019s NOX-A12 | Stryker acquires Vocera | Nuvalent\u2019s NVL-520","description":"Noxxon\u2019s NOX-A12 clinical trial; Exact Sciences buys PreventionGenetics; Nuvalent\u2019s clinical trails for NVL-520; Stryker acquires Vocera","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-noxxon-nuvalent-stryker-exact-sciences","og_locale":"en_US","og_type":"article","og_title":"Noxxon\u2019s NOX-A12 | Stryker acquires Vocera | Nuvalent\u2019s NVL-520","og_description":"Noxxon\u2019s NOX-A12 clinical trial; Exact Sciences buys PreventionGenetics; Nuvalent\u2019s clinical trails for NVL-520; Stryker acquires Vocera","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-noxxon-nuvalent-stryker-exact-sciences","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-01-11T17:35:38+00:00","article_modified_time":"2022-01-11T17:57:07+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/11230453\/Pharma-News-11.01.2022-1.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-noxxon-nuvalent-stryker-exact-sciences","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-noxxon-nuvalent-stryker-exact-sciences","name":"Noxxon\u2019s NOX-A12 | Stryker acquires Vocera | Nuvalent\u2019s NVL-520","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-noxxon-nuvalent-stryker-exact-sciences#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-noxxon-nuvalent-stryker-exact-sciences#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/11230453\/Pharma-News-11.01.2022-1.png","datePublished":"2022-01-11T17:35:38+00:00","dateModified":"2022-01-11T17:57:07+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Noxxon\u2019s NOX-A12 clinical trial; Exact Sciences buys PreventionGenetics; Nuvalent\u2019s clinical trails for NVL-520; Stryker acquires Vocera","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-noxxon-nuvalent-stryker-exact-sciences"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-noxxon-nuvalent-stryker-exact-sciences#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/11230453\/Pharma-News-11.01.2022-1.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/11230453\/Pharma-News-11.01.2022-1.png","width":772,"height":482,"caption":"pharma-news-for-noxxon-nuvalent-stryker-exact-sciences"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/11230453\/Pharma-News-11.01.2022-1-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">brain cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">glioblastoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NSCLC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">women\u2019s health<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">brain cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer research<\/span>","<span class=\"advgb-post-tax-term\">glioblastoma<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">NSCLC<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">women\u2019s health<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Jan 11, 2022","modified":"Updated on Jan 11, 2022"},"absolute_dates_time":{"created":"Posted on Jan 11, 2022 11:05 pm","modified":"Updated on Jan 11, 2022 11:27 pm"},"featured_img_caption":"pharma-news-for-noxxon-nuvalent-stryker-exact-sciences","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/15321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=15321"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/15321\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/15323"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=15321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=15321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=15321"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=15321"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=15321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}